A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.

ABSTRACT:

Background

Activation of the phosphoinisitide-3 kinase (PI3K) pathway through mutation and constitutive upregulation has been described in renal cell carcinoma (RCC), making it an attractive target for therapeutic intervention. We performed a randomized phase II study in vascular endothelial growth factor (VEGF) therapy refractory patients to determine whether MK-2206, an allosteric inhibitor of AKT, was more efficacious than the mammalian target of rapamycin inhibitor everolimus.

Patients and methods

A total of 43 patients were randomized in a 2:1 distribution, with 29 patients assigned to the MK-2206 arm and 14 to the everolimus arm. Progression-free survival (PFS) was the primary endpoint.

Results

The trial was closed at the first futility analysis with an observed

SUBMITTER: Jonasch E 

PROVIDER: S-EPMC5834088 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature